Last updated: October 02, 2026

Application No. 18/670,684

Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof

Non-Final OA

Filed

May 21, 2024

Priority

Jul 19, 2018 — provisional 62/700,615 +1 more

Examiner

BURKHART, MICHAEL D

Art Unit

Tech Center

Assignee

Regeneron Pharmaceuticals Inc.

OA Round

1 (Non-Final)

Interview Optional

— +11.7% interview lift. Interview lift (+11.7%) is below the 15.0% threshold. A written response is recommended.

Based on 839 resolved cases, 2023–2026

Examiner Intelligence

BURKHART, MICHAEL D View full profile →

Grants 62% of resolved cases

Career Allowance Rate

523 granted / 839 resolved

+2.3% vs TC avg

Moderate +12% lift

Without

With

+11.7%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

38 currently pending

Career history

872

Total Applications

across all art units

Statute-Specific Performance

§101

5.1%

-34.9% vs TC avg

§103

28.4%

-11.6% vs TC avg

§102

19.3%

-20.7% vs TC avg

§112

26.4%

-13.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 839 resolved cases

Prosecution Timeline

May 21, 2024

Application Filed

Sep 10, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/147,365

Patent 12747451

RNA ENCODING AN ANTIBODY

3y 9m to grant Granted Sep 29, 2026

17/921,291

Patent 12735727

STABILIZATION OF POLYETHYLENEIMINE-DEOXYRIBONUCLEIC ACID COMPLEX SIZE AND ACTIVITY

3y 10m to grant Granted Sep 15, 2026

18/597,328

Patent 12715918

METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY

2y 5m to grant Granted Aug 25, 2026

18/194,349

Patent 12708672

Vaccine and Uses thereof in Cell Therapy

3y 4m to grant Granted Aug 18, 2026

18/251,314

Patent 12698503

ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY CELL-BASED POTENCY ASSAY

3y 3m to grant Granted Aug 04, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

62%

Grant Probability

74%

With Interview (+11.7%)

3y 4m (~11m remaining)

Median Time to Grant

Low

PTA Risk

Based on 839 resolved cases by this examiner. Grant probability derived from career allowance rate.